Citigroup Maintains Buy on Zenas BioPharma, Raises Price Target to $48

Benzinga · 1d ago
Citigroup analyst Yigal Nochomovitz maintains Zenas BioPharma (NASDAQ:ZBIO) with a Buy and raises the price target from $41 to $48.